Research

Hormonal

Once-weekly efpeglenatide significantly reduces HbA1c and body weight in patients with type 2 diabetes and obesity, with a safety profile characterized by mild-to-moderate gastrointestinal side effects and low hypoglycemia risk.

Efpeglenatide is a once-weekly (or monthly) injection that helps lower blood sugar and lose weight in people with type 2 diabetes and obesity. It is generally well-tolerated, with common side effects like nausea being mild and temporary. It offers a convenient alternative to daily medications and has cardiovascular benefits for high-risk patients.

GoodSupportsHIGH confidence
The findings of these studies consistently indicate that efpeglenatide significantly reduces hemoglobin A1C (HbA1C), fasting plasma glucose (FPG), and body weight in patients with T2DM and obesity... The safety profile is similar to that of other GLP-1 RAs, with mild-to-moderate gastrointestinal side effects being the most common and a low risk of hypoglycemia, especially in patients not using insulin or sulfonylureas.
Neha Narayan et al. · Cureus · 2025

Why this rating

Based on a systematic review of 8 studies including RCTs, though some had moderate bias risk.

Source

Efficacy and Safety of Efpeglenatide in Patients With Type 2 Diabetes and Obesity: A Systematic Review

Neha Narayan et al. · Cureus · 2025

DOI 10.7759/cureus.77089

systematic_reviewCited 8×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →